Quotes 5-day view Delayed Nasdaq
05/23/2023
05/24/2023
05/25/2023
05/26/2023
05/30/2023
Date
204.37(c)
212.65(c)
193.53(c)
195.89(c)
194.51(c)
Last
753 912
1 987 922
3 777 572
1 782 677
1 320 769
Volume
-2.15%
+4.05%
-8.99%
+1.22%
-0.70%
Change
Estimated financial data (e) (USD)
Sales 2023
4 931 M
-
-
Net income 2023
45,1 M
-
-
Net Debt 2023
289 M
-
-
P/E ratio 2023
384x
Yield 2023
-
Sales 2024
5 720 M
-
-
Net income 2024
424 M
-
-
Net cash position 2024
1 217 M
-
-
P/E ratio 2024
69,8x
Yield 2024
-
Capitalization
30 752 M
30 752 M
-
EV / Sales 2023
6,29x
EV / Sales 2024
5,16x
Nbr of Employees
11 530
Free-Float
79,1%
llumina, Inc. est spécialisé dans le développement, la fabrication et la commercialisation de systèmes intégrés dédiés à l'analyse de la variation génétique et de la fonction biologique. Les produits du groupe sont destinés aux centres de recherche génomique, aux sociétés pharmaceutiques, aux institutions universitaires, aux organisations de recherche clinique et aux sociétés de biotechnologies. Le CA par source de...
Ratings of Illumina, Inc.
All news about ILLUMINA, INC.
News in other languages on ILLUMINA, INC.
Analyst Recommendations on ILLUMINA, INC.
ETFs positioned on ILLUMINA, INC. ETFs and Trackers with Trackinsight
Icahn wins one board seat at Illumina
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ILLUMINA, INC.
Short Term Mid-Term Long Term Trends Bearish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
194,51 $
Average target price
244,34 $
Spread / Average Target
25,6%
Please enable JavaScript in your browser's settings to use dynamic charts.